Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma

[1]  Xiaoping Chen,et al.  Adjuvant therapy following curative treatments for hepatocellular carcinoma: current dilemmas and prospects , 2023, Frontiers in Oncology.

[2]  P. Yang,et al.  Surgical Margin Affects the Long-Term Prognosis of Patients With Hepatocellular Carcinoma Undergoing Radical Hepatectomy Followed by Adjuvant TACE , 2023, The oncologist.

[3]  Yuan Cheng,et al.  Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Jinhua Zeng,et al.  Efficacy of Adjuvant Transarterial Chemoembolization Combined Antiviral Therapy for HBV-Related HCC with MVI after Hepatic Resection: A Multicenter Study , 2022, Asian Pacific journal of cancer prevention : APJCP.

[5]  Junxin Wu,et al.  Systematic review of adjuvant external beam radiotherapy for hepatocellular carcinoma following radical hepatectomy. , 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  A. Zhu,et al.  Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. , 2022, The Lancet. Oncology.

[7]  Yiwen Qiu,et al.  Efficacy of Postoperative Adjuvant Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients With Microscopic Portal Vein Invasion , 2022, Frontiers in Oncology.

[8]  Jiamei Yang,et al.  Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial. , 2022, European journal of cancer.

[9]  A. Pietras,et al.  Radiotherapy-induced remodeling of the tumor microenvironment by stromal cells. , 2022, Seminars in cancer biology.

[10]  Ying-bin Jia,et al.  Efficacy of Adjuvant Transarterial Chemoembolization after Radical Hepatectomy in Solitary Hepatocellular Carcinoma Patients: A Retrospective Study , 2022, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

[11]  L. Yang,et al.  Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements , 2022, Liver Cancer.

[12]  Vijay Kumar Chattu,et al.  Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 , 2021, JAMA oncology.

[13]  Jingfeng Liu,et al.  Meta-Analysis of Postoperative Adjuvant Hepatic Artery Infusion Chemotherapy Versus Surgical Resection Alone for Hepatocellular Carcinoma , 2021, Frontiers in Oncology.

[14]  T. Song,et al.  Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection , 2021, Frontiers in Oncology.

[15]  Dan Li,et al.  A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection , 2021, World Journal of Surgical Oncology.

[16]  S. Raman,et al.  Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  M. Deng,et al.  The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis , 2021, Cancer cell international.

[18]  Yinglu Guo,et al.  Narrow-Margin Hepatectomy Resulted in Higher Recurrence and Lower Overall Survival for R0 Resection Hepatocellular Carcinoma , 2021, Frontiers in Oncology.

[19]  W. Cong,et al.  Postoperative adjuvant transcatheter arterial chemoembolization improves the prognosis of patients with huge hepatocellular carcinoma. , 2021, Hepatobiliary & pancreatic diseases international : HBPD INT.

[20]  Weihu Wang,et al.  Adjuvant radiotherapy in central hepatocellular carcinoma after narrow-margin hepatectomy: A 10-year real-world evidence , 2020, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[21]  W. Dong,et al.  Postoperative adjuvant TACE-associated nomogram for predicting the prognosis of resectable Hepatocellular Carcinoma with portal vein Tumor Thrombus after Liver Resection , 2020, International journal of biological sciences.

[22]  D. Sinn,et al.  Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients , 2020, Clinical and molecular hepatology.

[23]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[24]  Mei Liu,et al.  Postoperative adjuvant treatment strategy for hepatocellular carcinoma with microvascular invasion: a non-randomized interventional clinical study , 2020, BMC Cancer.

[25]  Jingfeng Liu,et al.  The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study , 2020, Journal of Gastrointestinal Surgery.

[26]  Li Xu,et al.  Postoperative Adjuvant Transarterial Infusion Chemotherapy with FOLFOX Could Improve Outcomes of Hepatocellular Carcinoma Patients with Microvascular Invasion: A Preliminary Report of a Phase III, Randomized Controlled Clinical Trial , 2020, Annals of Surgical Oncology.

[27]  A. Nanashima,et al.  Increased Survival Benefit of Adjuvant Intra-arterial Infusion Chemotherapy in HCC Patients with Portal Vein Infiltration after Hepatectomy , 2020, World Journal of Surgery.

[28]  I. Endo,et al.  Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria , 2020, Annals of Surgical Oncology.

[29]  Zhao-You Tang,et al.  Targeting angiogenesis for liver cancer: Past, present, and future , 2020, Genes & diseases.

[30]  Zhongjun Wu,et al.  Adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis. , 2020, Clinics and research in hepatology and gastroenterology.

[31]  Wanzun Lin,et al.  Radiation-induced small extracellular vesicles as “carriages” promote tumor antigen release and trigger antitumor immunity , 2020, Theranostics.

[32]  Xiao-dong Zhu,et al.  Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects , 2020, Genes & diseases.

[33]  Z. Li,et al.  The efficacy of sorafenib in preventing hepatocellular carcinoma recurrence after resection: a systematic review and meta-analysis. , 2020, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[34]  Xiaozhen Zhang,et al.  A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma. , 2020, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[35]  W. Lau,et al.  Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus: An open-label randomized controlled trial. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[36]  Kang Wang,et al.  Adjuvant transarterial chemoembolization improves survival outcomes in hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[37]  D. Xie,et al.  Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis. , 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[38]  S. Miyayama.  Ultraselective conventional transarterial chemoembolization: When and how? , 2019, Clinical and molecular hepatology.

[39]  Bin Chen,et al.  Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma involving microvascular invasion. , 2019, American journal of surgery.

[40]  B. Xing,et al.  Postoperative adjuvant transcatheter arterial chemoembolization should be considered selectively in patients who have hepatocellular carcinoma with microvascular invasion. , 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[41]  K. Tanabe,et al.  Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma , 2019, Annals of Surgical Oncology.

[42]  Chuan Lan,et al.  Surgery combined with post-operative trancatheter arterial chemoembolization improves survival of intermediate hepatocellular carcinoma , 2019, Scandinavian journal of gastroenterology.

[43]  Q. Ye,et al.  Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion. , 2018, The oncologist.

[44]  W. Cong,et al.  Postoperative adjuvant transarterial chemoembolization for multinodular hepatocellular carcinoma within the Barcelona Clinic Liver Cancer early stage and microvascular invasion. , 2018, Hepatobiliary surgery and nutrition.

[45]  Li Xu,et al.  Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety , 2018, Cancer communications.

[46]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[47]  Lequn Li,et al.  Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion , 2017, World journal of gastroenterology.

[48]  Huei-Lung Liang,et al.  Adjuvant hepatic arterial infusion chemotherapy is beneficial for selective patients with Hepatocellular carcinoma undergoing surgical treatment. , 2017, International journal of surgery.

[49]  Mei Liu,et al.  Postoperative adjuvant radiotherapy is associated with improved survival in hepatocellular carcinoma with microvascular invasion , 2017, Oncotarget.

[50]  Jiayin Yang,et al.  Liver resection versus liver resection plus TACE for patients with hepatocellular carcinoma beyond Milan criteria. , 2017, The Journal of surgical research.

[51]  K. Wakayama,et al.  Huge hepatocellular carcinoma greater than 10 cm in diameter worsens prognosis by causing distant recurrence after curative resection , 2017, Journal of surgical oncology.

[52]  Jingxian Shen,et al.  Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. , 2017, Oncology letters.

[53]  W. Lau,et al.  Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. , 2016, World journal of gastroenterology.

[54]  B. Liu,et al.  Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. , 2016, World journal of gastroenterology.

[55]  W. Lau,et al.  Postoperative Adjuvant Transcatheter Arterial Chemoembolization After R0 Hepatectomy Improves Outcomes of Patients Who have Hepatocellular Carcinoma with Microvascular Invasion , 2016, Annals of Surgical Oncology.

[56]  Yan Zhang,et al.  Postoperative adjuvant arterial chemoembolization improves the survival of hepatitis B virus-related hepatocellular carcinoma: a retrospective control study , 2015, Irish Journal of Medical Science (1971 -).

[57]  Kristian Thorlund,et al.  The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations , 2015, Annals of Internal Medicine.

[58]  Wei Zhang,et al.  Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience. , 2014, Bioscience trends.

[59]  King-Teh Lee,et al.  Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[60]  Y. Maehara,et al.  Predictors for Microinvasion of Small Hepatocellular Carcinoma ≤2 cm , 2012, Annals of Surgical Oncology.

[61]  S. Ahn,et al.  Adjuvant Hepatic Arterial Infusional Chemotherapy with 5-Fluorouracil and Cisplatin after Curative Resection of Hepatocellular Carcinoma , 2011, Oncology.

[62]  A. Stang.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.

[63]  J. Llovet,et al.  A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. , 2009, Gastroenterology.

[64]  Tasha R. Stanton,et al.  Scales to Assess the Quality of Randomized Controlled Trials: A Systematic Review , 2008, Physical Therapy.

[65]  Bin Wang,et al.  Increased Expression of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization , 2008 .